Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Acumen Pharmaceuticals, Inc.
13G/A
ABOS · 00509G209
|
5.6% |
8/13/2025
Event 6/30/2025
|
|||
| Sands Capital Alternatives, LLC | 5.6% | ||||
| Sands Capital Ventures Discovery Fund III, L.P. | 1.9% | ||||
| Sands Capital Global Venture Fund II, L.P. | 1.9% | ||||
| Sands Capital Life Sciences Pulse Fund, LLC | 1.9% | ||||
| Sands Frank M. | 5.6% | ||||
|
Klaviyo, Inc.
13G/A
KVYO · 49845K101
|
4.9% |
5/14/2025
Event 3/31/2025
|
|||
| Sands Capital Ventures, LLC | 3.8% | ||||
| Sands Capital Global Innovation Fund II, L.P. | 2.5% | ||||
| Sands Capital Global Innovation Fund II-KLV, L.P. | 0.8% | ||||
| Sands Capital Global Innovation Fund-Public Opportunities, L.P. | 0% | ||||
| Sands Capital Management, LLC | 1.1% | ||||
| Sands Frank M. | 4.9% | ||||